SecBot SecBot
8-K ·Filed Feb 25, 2026

VCYT

VERACYTE, INC.
BULLISH
Impact 8/10
Horizonweeks Processed8mo ago SEC0001384101-26-000008
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong revenue growth, particularly in Decipher (27% growth) and Afirma tests, combined with margin expansion and robust cash flow, suggests improving fundamentals. The reiterated 2026 guidance provides visibility, but investors should monitor the impact of new product launches (Prosigna LDT, TrueMRD) on future growth.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$38.75
T+0 close · Feb 25, 2026 · via day close
Latest settled
+16.21%
T+60 · $45.03
Vs SPY
+8.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $38.75entry
  2. T+1 · 9mo ago −5.57%α −5.09% · $36.59
  3. T+5 · 9mo ago −10.50%α −9.34% · $34.68
  4. T+20 · 8mo ago −15.35%α −8.94% · $32.80
  5. T+60 · 6mo ago +16.21%α +8.03% · $45.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Veracyte reported strong fourth quarter and full year 2025 financial results, with Q4 total revenue up 19% year-over-year to $140.6 million and full year revenue up 16% to $517.1 million. The company delivered GAAP net income of $66.4 million and generated $136.3 million in operating cash flow. Management reiterated 2026 revenue guidance of 10-13% growth.

Key Financial Metrics

Revenue
$517.1M
+16.0% YoY
Adj. EPS
$1.78
GAAP: $0.82
Guidance
$570M-$582M
maintained
Gross Margin
70.1%

Key Facts

  • Q4 2025 total revenue: $140.6 million (19% YoY growth)
  • Full year 2025 total revenue: $517.1 million (16% YoY growth)
  • Q4 2025 GAAP net income: $41.1 million (29.3% of revenue)
  • Full year 2025 GAAP net income: $66.4 million (12.8% of revenue)
  • Generated $136.3 million in cash from operations for full year 2025
  • Reiterated 2026 revenue guidance of $570-$582 million (10-13% growth)

Financial Impact

Revenue growth of 16-19% and net income growth of 175% YoY with strong cash flow generation of $136.3 million

revenueepsnet incomecashFlow

Segment Breakdown

SegmentRevenueGrowth
Decipher$310.7M+27.0%
Afirma$172.9M+9.0%

Risk Factors

  • Biopharmaceutical and other revenue declined due to restructuring of Veracyte SAS
  • Future guidance excludes contribution from new tests, creating uncertainty about full-year performance
  • Adjusted EBITDA margin expected to decrease to ~25% in 2026 from 27.6% in 2025

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001384101-26-000008
Document: vcyt-20260225.htm0001384101-26-000008
Document: 0001384101-26-000008-index-headers.html0001384101-26-000008
Document: 0001384101-26-000008-index.html0001384101-26-000008
Document: 0001384101-26-000008.txt0001384101-26-000008

Track record

22 reports on VCYT

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +20.37% at T+20 after the Jun 11, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $24.63 Now $24.01 −2.52% settles Dec 11
  2. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $24.00 Now $24.01 +0.04% settles Dec 4
  3. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $24.00 Now $24.01 +0.04% settles Dec 4
  4. Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $50.01 Now $24.01 −51.99% settles Nov 30
  5. Oct 28, 202619d ago Insider Cluster Neutral 2/10 Entry $52.17 Now $24.01 −53.98% settles Nov 27
  6. Oct 28, 202619d ago Insider Cluster Neutral 3/10 Entry $52.17 Now $24.01 −53.98% settles Nov 27
  7. Oct 27, 202620d ago 144 Neutral 2/10 Entry $50.31 Now $24.01 −52.28% settles Nov 25
  8. Oct 27, 202620d ago 144 Neutral 2/10 Entry $50.31 Now $24.01 −52.28% settles Nov 25
  9. Sep 22, 20267w ago Insider Cluster Neutral 2/10 Entry $43.82 to $46.22 Now $24.01 −45.21% ▲ +5.48% +4.79% vs SPY
  10. Sep 14, 20269w ago Press Release Bullish 6/10 Entry $40.14 to $43.11 Now $24.01 −40.18% ▲ +7.40% +4.68% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 9h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026